Start a ProjectMICRONEEDLE APPLICATION
The payload and target product profile must be translated into a formulation, structure and process that preserve critical performance attributes.
The assessment begins by defining the payload, target dose, intended use, release objective, available data and manufacturing constraints that shape the project pathway.
CASMN defines project-appropriate feasibility, formulation, mechanical, delivery, analytical and process studies.
Technology selection depends on payload properties, dose, release requirements, intended use and manufacturing constraints.
Non-confidential review → feasibility assessment → formulation and prototype development → analytical and performance evaluation → process development → pilot scale-up planning.
Relevant CASMN team publications are used as scientific context. Published research does not by itself establish product approval, clinical performance or commercial readiness.
References to exenatide and related payloads describe published research only. They do not represent an approved or commercial GLP-1 microneedle product or a proven replacement for injection. Technical Review — Reviewed by: CASMN R&D Team · Last reviewed: August 2026.
The team reviews payload properties, target dose, stability, intended use, delivery requirements and manufacturing constraints.
Technology selection is made project by project after reviewing dose, release profile, product use and process requirements.
No. Publications provide scientific context and do not establish regulatory approval, clinical performance or commercial availability.
Send your target product, payload, development stage and cooperation scope to our business development team.
Start a Project